Shareholder alert: ademi llp investigates whether revance therapeutics, inc. is obtaining a fair price for its public shareholders

Milwaukee--(business wire)--ademi llp is investigating revance (nasdaq: rvnc) for possible breaches of fiduciary duty and other violations of law in its transaction with crown. click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. there is no cost or obligation to you. in the revised transaction, revance stockholders will receive only $3.10 per share in cash, less than one-half of the august 2024 purc.
RVNC Ratings Summary
RVNC Quant Ranking